General
Preferred name
bromocriptine
Synonyms
BROMOCRIPTINE MESYLATE ()
(+)-Bromocriptine methanesulfonate ()
CB-154 ()
Bromocryptine mesylate ()
Bromocriptin mesylate ()
CB-154 mesylate ()
Bromocriptine mesilate ()
2-bromoergocryptine mesylate ()
Parlodel ()
NSC-755915 ()
Bromocriptine methanesulfonate ()
Cb-154 mesilate ()
Cycloset ()
Ergocryptine, 2-bromo- ()
Bromocriptina ()
Bromergocryptine ()
SANDOZ 15-754 ()
2-bromo-.alpha.-ergocryptine ()
Bromocriptine (mesylate) ()
Bromocriptine-13C-d3 ()
P&D ID
PD009743
CAS
22260-51-1
25614-03-3
Tags
available
biased GPCR ligand
drug
Approved by
FDA
First approval
1978
Drug indication
Parkinson disease
Enzyme Inhibitor (prolactin)
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Bromocriptine exhibits potent dopaminergic activity. (GtoPdb)
DESCRIPTION Selective D2-like agonist (Tocriscreen Plus)
DESCRIPTION D2 dopamine receptor agonist; inhibits prolaction secretion (LOPAC library)
DESCRIPTION Selective D2-like agonist (Tocriscreen Total)
DESCRIPTION beta agonist (Tocris Bioactive Compound Library)
Cell lines
0
Organisms
6
Compound Sets
33
AdooQ Bioactive Compound Library
A13705
BiasDB
Bromocriptine
Cayman Chemical Bioactives
14598
26669
ChEMBL Approved Drugs
CHEMBL1200503
CHEMBL493
ChEMBL Drugs
CHEMBL1200503
CHEMBL493
Concise Guide to Pharmacology 2017/18
35
Concise Guide to Pharmacology 2019/20
35
Concise Guide to Pharmacology 2021/22
35
Concise Guide to Pharmacology 2023/24
35
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB01200
DrugBank Approved Drugs
DB01200
DrugCentral
403
DrugCentral Approved Drugs
403
DrugMAP
DMVE3TK
DrugMAP Approved Drugs
DMVE3TK
EU-OPENSCREEN Bioactive Compound Library
EOS101129
Guide to Pharmacology
35
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1200503
CHEMBL493
NCATS Inxight Approved Drugs
3A64E3G5ZO
NIH Mechanistic Set
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
T5842
Tocris Bioactive Compound Library
0427
Tocriscreen Plus
0427
Tocriscreen Total
Withdrawn 2.0
w199
ZINC Tool Compounds
ZINC000053683151
External IDs
68
Properties
(calculated by RDKit )
Molecular Weight
653.22
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
7
Aromatic Ring Count
2
cLogP
3.19
TPSA
118.21
Fraction CSP3
0.59
Chiral centers
6.0
Largest ring
6.0
QED
0.46
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
7-TM Receptors
Selectivity
D2
Pathway
Neuroscience
GPCR/G protein
Primary Target
Non-selective Dopamine
MOA
Agonist
Dopamine D2 Agonists
Prolactin Secretion Inhibitors
Dopamine Receptor agonist
Member status
virtual
Disease Area
endocrinology, neurology/psychiatry
Indication
hyperprolactinemia, Parkinson's Disease, acromegaly
Target
ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7
ATC
G02CB01
N04BC01
Toxicity type
neurological
Therapeutic Class
Antiparkinson Agents
Source data